Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health insider Melissa Baird filed a Form 144 notifying a proposed sale of 33,333 Class A common shares through Goldman Sachs & Co. LLC, with an aggregate market value of $1,598,650.68. The filing states the shares were acquired on 05/13/2020 as compensation via stock options and that the planned payment method is a cashless exercise/same-day sale. The document lists 217,641,958 shares outstanding for the class and discloses multiple individual sales by Ms. Baird during May–July 2025 with specific dates, share amounts and gross proceeds. No earnings, guidance or other corporate actions are included in this filing.
Hims & Hers Health insider Boughton Soleil, the company's Chief Legal Officer, reported a sale of 2,572 shares of Class A common stock on 08/11/2025 at a reported price of $51.64 per share, leaving 153,021 shares beneficially owned. The filing is a Section 16 Form 4 disclosing this change in beneficial ownership.
Andrew Dudum, identified as Chief Executive Officer, director and a 10% owner of Hims & Hers Health, Inc. (HIMS), reported a sale of Class A common stock on 08/07/2025. The Form 4 shows a disposition of 660,000 shares reported as a sale (code S) at an average weighted price of $50.582 per share.
The filing itemizes the reporting person’s remaining beneficial holdings held indirectly through multiple trusts. The form shows 2,214,769 shares noted alongside the Dudum Family Heritage Trust, and additional indirect trust holdings listed as 1,194,545, 990,410, 1,286,627, 534,491, 186,723, 190,126, 321,657, 1,584,506 and 829,185 shares. The Form 4 was signed by an attorney-in-fact.
Form 144 notice: The filing reports a proposed sale of 2,572 Class A shares of Hims & Hers Health, Inc. through Fidelity Brokerage Services LLC on 08/11/2025, with an aggregate market value of $132,818.08. The company has 217,641,958 shares outstanding. The 2,572 shares were acquired on 06/15/2025 through restricted stock vesting from the issuer and were recorded as compensation.
The filing also lists recent sales by Soleil Boughton over the prior three months: seven transactions between 05/12/2025 and 07/28/2025 totaling 22,207 shares for aggregate gross proceeds of $1,228,936.95. The form includes the standard insider representation regarding material nonpublic information.
Hims & Hers Health director David B. Wells was granted 3,656 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Class A common stock. The award is recorded with a $0 per‑unit price and is reported as direct beneficial ownership. The RSUs vest upon continuous service on the earlier of the company’s 2026 annual meeting or June 15, 2026, and the transaction date on the form is 08/06/2025. The filing documents a routine equity grant to a director with vesting tied to continued service.
Christopher D. Payne, a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A common stock, and the reported beneficial ownership following the grant is 3,656 shares held directly.
The RSUs vest upon the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, and are subject to continuous service. The award carries no exercise price and converts one-for-one into Class A common stock when vested, increasing the director’s direct equity stake but remaining subject to standard service and vesting conditions.
Andrea Perez Garcia, identified as a Director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) with an indicated price of $0 on 08/06/2025. The Form 4 reports the award as a derivative security and shows 3,656 shares beneficially owned following the transaction, held in a direct ownership form.
The filing explains each RSU is a contingent right to receive one share of Class A Common Stock and that the RSUs will vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026, subject to continuous service. The Form 4 was signed by an attorney-in-fact on 08/08/2025.
Cosgrove Delos M., a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A Common Stock, with an indicated price of $0 per unit. Following the grant, the reporting person beneficially owns 3,656 shares on a direct basis.
The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, so the award is structured as a near-term retention/compensation award that will convert into ordinary shares if service conditions are met.
Hims & Hers Health director Deborah M. Autor was granted 3,656 Restricted Stock Units (RSUs) that convert one-for-one into Class A common shares. The award was recorded as an acquisition of derivative securities and increases her direct beneficial ownership to 3,656 shares at a reported price of $0. The RSUs are subject to a service-based vesting schedule and will vest on the earlier of the company’s 2026 annual meeting or June 15, 2026, provided continuous service.
This filing reflects an equity grant to a board director rather than a cash transaction or sale, creating potential alignment between the director and shareholders through future ownership if vesting conditions are met.
Carroll Patrick Harrison, Chief Medical Officer and a director of Hims & Hers Health, Inc. (HIMS), reported the sale of 60,000 shares of Class A common stock on 08/06/2025 at a weighted average price of $53.5813 per share (sales ranged from $53.19 to $53.97). After the sale his direct beneficial ownership of Class A shares is reported as 169,940 shares.
The filing also discloses a grant of 3,656 Restricted Stock Units (RSUs) that each convert into one share of Class A common stock subject to continuous service; the RSUs vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026. The filer represents the sale price as an average weighted price and offers to provide further allocation details upon request.